跳至主要内容
临床试验/NCT05049720
NCT05049720撤回不适用

ExtraVascular Implantable Cardiac Defibrillator Continued Access Study

Medtronic0 个研究点开始时间: 2022年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
Medtronic
主要终点
Complications

研究概览

简要总结

This study is designed to provide continued access to the Extravascular Implantable Cardioverter Defibrillator (EV ICD) System.

详细描述

The study will enroll subjects who are indicated to receive an implantable defibrillator who meet all of the inclusion criteria and none of the exclusion criteria. Subjects will receive an investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system, in which a lead is placed outside of the heart and veins to deliver defibrillation therapy. Subjects will be followed every 6 months following system implantation.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient has a Class I or IIa indication for implantation of an ICD according to the ACC/AHA/HRS Guidelines.[1]
  • Patient is willing and able to sign and date the Informed Consent Form for their participation in the study.
  • Patient is at least 18 years of age and meets age requirements per local law.
  • Patient is geographically stable and willing and able to comply with the study procedures and visits for the duration of the follow-up.

排除标准

  • Patient has indications for bradycardia pacing[2] or Cardiac Resynchronization Therapy (CRT)[3] (Class I, IIa, or IIb indication).
  • Patients with an existing pacemaker, ICD, or CRT device or leads.
  • Patients with these medical interventions are excluded from participation in the study:
  • Prior sternotomy
  • Any prior medical condition or procedure that leads to adhesions in the anterior mediastinal space (i.e., prior mediastinal instrumentation, mediastinitis)
  • Prior abdominal surgery in the epigastric region
  • Planned sternotomy
  • Prior chest radiotherapy
  • Or any other prior/planned medical intervention not listed that precludes their participation in the opinion of the Investigator.
  • Patients with these medical conditions or anatomies are excluded from participation in the study:
  • Hiatal hernia that distorts mediastinal anatomy
  • Marked sternal abnormality (e.g., pectus excavatum that impedes the substernal tunneling path or procedure)
  • Decompensated heart failure
  • COPD with oxygen dependence
  • Gross hepatosplenomegaly
  • Or any other known medical condition or anatomy type not listed that precludes their participation in the opinion of the Investigator.
  • Patients with a medical condition that precludes them from undergoing defibrillation testing:
  • Severe aortic stenosis
  • Current Intracardiac LA or LV thrombus
  • Severe proximal three-vessel or left main coronary artery disease without revascularization
  • Hemodynamic instability
  • Unstable angina
  • Recent stroke or transient ischemic attack (within the last 6 months)
  • Known inadequate external defibrillation
  • LVEF < 20%
  • LVEDD >70 mm
  • Or any other known medical condition not listed that precludes their participation in the opinion of the Investigator.
  • Patient with any evidence of active infection or undergoing treatment for an infection.
  • Patient is contraindicated from temporary suspension of oral/systemic anticoagulation.
  • Patient with current implantation of neurostimulator or any other chronically implanted device that delivers current in the body.
  • Patient meets ACC/AHA/HRS or ESC clinical guideline Class III criteria for an ICD (e.g., life expectancy of less than 12 months).
  • Patient is enrolled or planning to enroll in a concurrent clinical study that may confound the results of this study, without documented pre-approval from a Medtronic study manager.
  • Patient with any exclusion criteria as required by local law (e.g., age or other).
  • Pregnant women or breastfeeding women, or women of childbearing potential and who are not on a reliable form of birth regulation method or abstinence*
  • (*If required by local law, women of child-bearing potential must undergo a pregnancy test within seven days prior to EV ICD Continued Access Study procedures)

结局指标

主要结局

Complications

时间窗: Through study completion, an average of 18 months

EV ICD system and/or procedure related adverse events

次要结局

未报告次要终点

研究者

发起方
Medtronic
申办方类型
Industry
责任方
Sponsor

相似试验